Arcturus Therapeutics

Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics
Arcturus Therapeutics has built a multicultural team, based in San Diego, CA, USA
We have an exciting COVID-19 vaccine candidate that we hope will make a positive difference in the pandemic
See our team describe what it means for them to help get a vaccine to protect people around the world-no matter where you are from
A
S
L
https://arcturusrx.com/wp-content/uploads/2023/01/JoePayne_LanguageProficiency_V3_1.mp4
arabic
(عربى)
https://arcturusrx.com/wp-content/uploads/2023/01/MaherA_LanguageProficiency_V3_1.mp4
chinese
(中文)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_BelleBao.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/BelleBao_LanguageProficiency__V3_1.mp4
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_HowardYu.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/HowardYu_LanguageProficiency_V3_1.mp4
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_YurongGuo.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/YurongGuo_LanguageProficiency_V3_1.mp4
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_XuefengGuo.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/XuefengGuo_LanguageProficiency_V3_1.mp4
english
(British)
https://arcturusrx.com/wp-content/uploads/2023/01/MikeHodges_LanguageProficiency_V3_1.mp4
farsi
(فارسی)
https://arcturusrx.com/wp-content/uploads/2023/01/NedaSafarzadeh_LanguageProficiency_V5.mp4
french
(Français)
https://arcturusrx.com/wp-content/uploads/2023/01/NadjaEl-mecharrafie_LanguageProficiency_V3_1.mp4
german
(deutsch)
https://arcturusrx.com/wp-content/uploads/2023/01/LisaKieweg-Thompson_LanguageProficiency_V3_1.mp4
hebrew
(עִברִית)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_NoaScott.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/NoaScott_LanguageProficiency_V3_1.mp4
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_TamarGrossman.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/TamarGrossman_LanguageProficiency_V3_1.mp4
hindi
(हिन्दी)
https://arcturusrx.com/wp-content/uploads/2023/01/PriyaKarmali_LanguageProficiency_V3_1.mp4
italian
(italiano)
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_CristianoSacchetti.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/CristianoSacchetti_LanguageProficiency_V3_1.mp4
https://arcturusrx.com/wp-content/uploads/2023/01/thumbnail_GiulioCattarossi.jpg,https://arcturusrx.com/wp-content/uploads/2023/01/GiulioCattarossi_LanguageProficiency_V3_1.mp4
Japanese
(日本語)
https://arcturusrx.com/wp-content/uploads/2023/01/Kiyoshi_Tachikawa_v2.mp4
korean
(한국어)
https://arcturusrx.com/wp-content/uploads/2023/01/JaeHeonKim_LanguageProficiency_V3_1.mp4
portuguese
(Português)
https://arcturusrx.com/wp-content/uploads/2023/01/RamonDiazTrelles_LanguageProficiency_V3_1.mp4
spanish
(español)
https://arcturusrx.com/wp-content/uploads/2023/01/CarlosPerezGarcia_LanguageProficiency__V3_1.mp4
vietnamese
(Tiếng Việt)
https://arcturusrx.com/wp-content/uploads/2023/01/HannahHuynh_LanguageProficiency_V3_1.mp4

News & Events

September 26, 2023
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
September 19, 2023
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
September 5, 2023
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
August 17, 2023
Arcturus Therapeutics to Attend Upcoming Investor Conferences
August 14, 2023
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
August 7, 2023
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
July 24, 2023
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
June 1, 2023
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
May 9, 2023
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
April 26, 2023
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
March 28, 2023
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
January 31, 2023
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
December 19, 2022
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 13, 2022
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
December 12, 2022
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
November 9, 2022
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
November 8, 2022
Arcturus Therapeutics to Present at the Following Investor Conferences in November
November 1, 2022
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
October 26, 2022
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
September 27, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences

LUNAR® Mechanism of Delivery